Skip to main content

Mount Sinai and Aarhus University Researchers Find No Increased Risk of Developmental Disorders from In Utero ADHD Medication Exposure

Veerle Bergink, MD, PhD, Director of Mount Sinai’s Women’s Mental Health Program

Veerle Bergink, MD, PhD, director of Mount Sinai’s Women’s Mental Health Program, and researchers at the Center for Register-based Research at Aarhus University have found that there were no changes in the likelihood of developing neurodevelopmental disorders among children exposed to ADHD medication in utero. This study is the first to examine in utero exposure to stimulants and long term child outcomes. Researchers examined almost 900 children who were exposed to ADHD during the mothers’ pregnancy and 1270 children who were not.

Learn More